Indian Company Allowed To Market Biologic Therapy For COVID-19 Patients
India’s Biocon has received approval from the country’s drug regulator to market, Itolizumab injection, to treat cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) in COVID-19 patients, a company statement said. In 2013, Biocon had launched Itolizumab, an anti-CD6 IgG1 monoclonal antibody biologic therapy for treating chronic plaque psoriasis, which … Read more